| Literature DB >> 30354701 |
Yi-Hua Lee1,2, Gi-Ming Lai3,4, De-Chih Lee2, Lee-Jang Tsai Lai5, Yuan-Ping Chang6.
Abstract
OBJECTIVES: Cancer-related fatigue and fear of recurrence (FOR) are the most common symptoms in cancer survivors and severely affect quality of life (QOL). This study aims to promote and evaluate the effectiveness of physical and psychological rehabilitation activities for cancer survivors.Entities:
Keywords: Qigong exercise; cancer survivors; cancer-related fatigue; fear of recurrence; heart rate variability; quality of life; stress management
Mesh:
Year: 2018 PMID: 30354701 PMCID: PMC6247550 DOI: 10.1177/1534735418805149
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Figure 1.CONSORT flow diagram of this study.
A Pilot Study for Factor Analysis of Cancer-Related Fatigue and Fear of Recurrence Scales.
| Cancer-Related Fatigue (CRF) | Factor | ||
|---|---|---|---|
| 1 | 2 | 3 | |
| Lifestyle Function | Mind-Body Function | Sleep Condition | |
| Difficulty completing daily tasks attributed to feeling fatigued | 0.855 | ||
| Significant diminished energy in daily life or social of functioning | 0.811 | ||
| Decreased motivation or interest to engage in usual activities | 0.768 | ||
| Perceived need to struggle to overcome inactivity | 0.750 | ||
| Perceived problems with short-term memory | 0.865 | ||
| Diminished concentration or attention | 0.845 | ||
| Complaints of generalized weakness or limb heaviness | 0.750 | ||
| Post-exertional malaise lasting several hours | 0.667 | ||
| Hypersomnia | 0.893 | ||
| Experience of sleep as unrefreshing or nonrestorative | 0.796 | ||
| Cronbach’s α: | |||
| Factor 1 = 0.873 | KMO = 0.839, χ2 = 541.686 | ||
| Factor 2 = 0.864 | Total variance explained 87.8% | ||
| Factor 3 = 0.715 | |||
| Fear of Recurrence (FOR) | Factor | ||
| 1 | 2 | 3 | |
| Psychological Distress | Lifestyle Function | Triggers | |
| Sadness, discouragement, or disappointment | 0.858 | ||
| Worry, fear, or anxiety | 0.833 | ||
| Helplessness or resignation | 0.780 | ||
| Frustration, anger, or outrage | 0.779 | ||
| I am worried or anxious about the FOR | 0.774 | ||
| I am afraid of a cancer recurrence | 0.768 | ||
| When I think about FOR, other unpleasant thoughts or images come to mind (death, suffering consequences for my family) | 0.748 | ||
| My social or leisure activities (eg, outings, sports, travel) | 0.880 | ||
| My work or everyday activities | 0.866 | ||
| My relationship with my partner, my family, or those close to me | 0.836 | ||
| My quality of life in general | 0.762 | ||
| My ability to make future plans or set life goals | 0.690 | ||
| Seeing or hearing someone who is ill | 0.859 | ||
| Going to funeral or reading the obituary section of the paper | 0.768 | ||
| Television shows or newspaper articles about cancer or illness | 0.684 | ||
| Cronbach’s α: | |||
| Factor 1 = 0.956 | KMO = 0.915, χ2 = 1254.630 | ||
| Factor 2 = 0.936 | Total variance explained 95.4% | ||
| Factor 3 = 0.794 | |||
Abbreviations: KMO, Kaiser-Meyer-Olkin.
P < .001
Demographic Characteristics of Participants at Baseline.
| Frequency Distribution (%) | ||||||
|---|---|---|---|---|---|---|
| Characteristics | E1 (n = 29) | E2 (n = 25) | Control (n = 26) | Total (N = 80) | χ2 Test |
|
| Gender | 0.705 | .703 | ||||
| Male | 4 (13.8%) | 2 (8.0%) | 4 (15.4%) | 10 (12.5%) | ||
| Female | 25 (86.2%) | 23 (92.0%) | 22 (84.6%) | 70 (87.5%) | ||
| Age (years) | 3.848 | .871 | ||||
| 30-39 | 3 (10.3%) | 1 (4.0%) | 1 (3.8%) | 5 (6.3%) | ||
| 40-49 | 7 (24.1%) | 6 (24.0%) | 5 (19.2%) | 18 (22.5%) | ||
| 50-59 | 11 (37.9%) | 12 (48.0%) | 15 (57.7%) | 38 (47.5%) | ||
| 60-69 | 5 (17.2%) | 5 (20.0%) | 3 (11.5%) | 13 (16.3%) | ||
| 70-75 | 3 (10.3%) | 1 (4.0%) | 2 (7.7%) | 6 (7.5%) | ||
| Marital status | 7.013 | .535 | ||||
| Single | 4 (13.8%) | 3 (12.0%) | 5 (19.2%) | 12 (15.0%) | ||
| Married | 23 (79.3%) | 19 (76.0%) | 15 (57.7%) | 57 (71.3%) | ||
| Separation | 1 (3.4%) | 1 (4.0%) | 1 (3.8%) | 3 (3.8%) | ||
| Divorced | 0 (0.0%) | 1 (4.0%) | 4 (15.4%) | 5 (6.3%) | ||
| Widowed | 1 (3.4%) | 1 (4.0%) | 1 (3.8%) | 3 (3.8%) | ||
| Education | 11.041 | .199 | ||||
| Below high school | 3 (10.3%) | 1 (4.0%) | 6 (23.0%) | 10 (12.5%) | ||
| High school | 6 (20.7%) | 9 (36.0%) | 7 (26.9%) | 22 (27.5%) | ||
| College and higher | 20 (68.9%) | 15 (60.0%) | 13 (50.0%) | 48 (60.0%) | ||
| Survival period | 12.402 | .015 | ||||
| Within 5 years | 25 (86.2%) | 14 (56.0%) | 17 (65.4%) | 56 (70.0%) | ||
| 5-10 years | 2 (6.9%) | 11 (44.0%) | 6 (23.1%) | 19 (23.8%) | ||
| >10 years | 2 (6.9%) | 0 (0.0%) | 3 (11.5%) | 5 (6.3%) | ||
| Cancer type | 4.149 | .940 | ||||
| Colorectal cancer | 2 (6.9%) | 2 (8.0%) | 3 (11.5%) | 7 (8.8%) | ||
| Lung cancer | 1 (3.4%) | 1 (4.0%) | 1 (3.8%) | 3 (3.8%) | ||
| Malignant lymphoma | 1 (3.4%) | 3 (8.0%) | 0 (0.0%) | 3 (3.8%) | ||
| Breast cancer | 18 (62.1%) | 16 (64.0%) | 18 (69.2%) | 52 (65.0%) | ||
| Gynecological cancer | 2 (6.9%) | 2 (8.0%) | 2 (7.7%) | 6 (7.5%) | ||
| Other types of cancer[ | 5 (17.2%) | 2 (8.0%) | 2 (7.7%) | 9 (11.3%) | ||
| Cancer staging | 5.097 | 0.531 | ||||
| None stage[ | 1 (3.4%) | 1 (4.0%) | 1 (3.8%) | 3 (3.7%) | ||
| I | 7 (24.1%) | 11 (44.0%) | 11 (42.3%) | 29 (36.3%) | ||
| II | 15 (51.7%) | 7 (28.0%) | 7 (26.9%) | 29 (36.3%) | ||
| III | 6 (20.7%) | 6 (24.0%) | 7 (26.9%) | 19 (23.8%) | ||
| Sense of fatigue | 0.622 | .733 | ||||
| No | 12 (41.4%) | 10 (40.0%) | 13 (50.0%) | 35 (43.8%) | ||
| Yes | 17 (58.6%) | 15 (60.0%) | 13 (50.0%) | 45 (56.3%) | ||
| Sense of anxiety | 0.010 | .995 | ||||
| No | 22 (75.9%) | 19 (76.0%) | 20 (76.9%) | 61 (76.3%) | ||
| Yes | 7 (24.1%) | 6 (24.0%) | 6 (23.1%) | 19 (23.8%) | ||
| Sense of depression | 1.126 | .569 | ||||
| No | 22 (75.9%) | 17 (68.0%) | 21 (80.8%) | 60 (75.0%) | ||
| Yes | 7 (24.1%) | 8 (32.0%) | 5 (19.2%) | 20 (25.0%) | ||
| Level of CRF at baseline | 4.188 | .381 | ||||
| None (score of 1-6) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
| Mild (score of 7-20) | 5 (17.2%) | 4 (16.0%) | 9 (34.6%) | 18 (22.5%) | ||
| Moderate (score of 21-35) | 21 (72.4%) | 20 (80.0%) | 15 (57.7%) | 56 (70.0%) | ||
| Severe (score of 36-50) | 3 (10.3%) | 1 (4.0%) | 2 (7.7%) | 6 (7.5%) | ||
| Level of FOR at baseline | 4.259 | .642 | ||||
| None (score of 1-15) | 1 (3.4%) | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | ||
| Mild (score of 16-35) | 15 (51.7%) | 11 (44.0%) | 15 (57.7%) | 41 (51.2%) | ||
| Moderate (score of 36-55) | 10 (34.5%) | 13 (52.0%) | 9 (34.6%) | 32 (40.0%) | ||
| Severe (score of 56-75) | 3 (10.3%) | 1 (4.0%) | 2 (7.7%) | 6 (7.5%) | ||
Abbreviations: E1, Qigong exercise group; E2, stress management group; CRF, cancer-related fatigue; FOR, fear of recurrence.
Other types of cancer including gastric cancer, liver cancer, leukemia, nasopharyngeal carcinoma, and peritoneal mesothelioma.
None stage including leukemia and peritoneal mesothelioma.
The Paired Sample t Test and 1-Way ANOVA of 3 Groups (N = 80).
| Variables | Improvement Effects of Single Interventions[ | Between-Group Effects[ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 vs T0 | T2 vs T0 | T2 vsT1 | T1-T0 | T2-T0 | |||||||||
| Mean (SD) |
|
| Mean (SD) |
|
| Mean (SD) |
|
| F |
| F |
| |
| CRF | 1.850 | .164 | 1.416 | .249 | |||||||||
| E1 | −0.213 (0.499) | −2.307 | .029 | −0.213 (0.550) | −2.093 | .046 | 0.000 (0.376) | 0.000 | 1.000 | ||||
| E2 | −0.228 (0.514) | −2.216 | .036 | −0.212 (0.506) | −2.095 | .047 | 0.016 (0.484) | 0.165 | .870 | ||||
| Control | 0.026 (0.602) | 0.228 | .822 | 0.015 (0.640) | 0.122 | .903 | −0.011 (0.554) | −0.106 | .916 | ||||
| FOR | 0.957 | .389 | 0.750 | .476 | |||||||||
| E1 | −0.147 (0.687) | −1.153 | .259 | −0.211 (0.751) | −1.516 | .141 | −0.064 (0.437) | −0.793 | .453 | ||||
| E2 | −0.173 (0.495) | −1.750 | .093 | −0.090 (0.619) | −0.732 | .471 | 0.082 (0.422) | 0.979 | .337 | ||||
| Control | 0.028 (0.493) | 0.292 | .773 | −0.007 (0.436) | −0.090 | .929 | −0.035 (0.439) | −0.417 | .680 | ||||
| QOL | 1.092 | .341 | 0.116 | .890 | |||||||||
| E1 | 0.168 (0.587) | 1.545 | .134 | 0.026 (0.674) | 0.212 | .834 | −0.141 (0.476) | −1.603 | .120 | ||||
| E2 | 0.090 (0.386) | 1.173 | .252 | 0.078 (0.370) | 1.057 | .301 | −0.012 (0.337) | −0.182 | .857 | ||||
| Control | −0.017 (0.377) | −0.240 | .813 | 0.011 (0.431) | 0.140 | .890 | 0.029 (0.284) | 0.529 | .601 | ||||
| SDNN | 9.332 | <.001 | 0.272 | .763 | |||||||||
| E1 | 5.267 (5.657) | 5.014 | <.001 | 1.178 (8.217) | 0.772 | .446 | −4.088 (10.036) | −2.194 | .037 | ||||
| E2 | 8.390 (5.274) | 7.954 | <.001 | 2.369 (11.085) | 1.069 | .296 | −6.021 (10.922) | −2.756 | .011 | ||||
| Control | −0.881 (11.230) | −0.400 | .692 | 0.140 (12.851) | 0.056 | .956 | 1.021 (6.737) | 0.773 | .447 | ||||
| TP | 7.307 | .001 | 2.129 | .126 | |||||||||
| E1 | 203.008 (317.483) | 3.443 | .002 | 47.782 (252.675) | 1.018 | .317 | −155.225 (403.743) | −2.070 | .048 | ||||
| E2 | 255.459 (259.103) | 4.930 | <.001 | 55.154 (369.998) | 0.745 | .463 | −200.304 (380.110) | −2.635 | .015 | ||||
| Control | −72.903 (404.670) | −0.919 | .367 | −9.673 (479.527) | −0.103 | .919 | 63.230 (237.924) | 1.355 | .188 | ||||
| HF | 0.943 | .394 | 0.280 | .756 | |||||||||
| E1 | 35.358 (59.786) | 3.185 | .004 | 2.733 (77.064) | 0.191 | .850 | −32.625 (89.502) | −1.963 | .060 | ||||
| E2 | 34.447 (77.034) | 2.236 | .035 | 18.478 (144.497) | 0.639 | .529 | −15.969 (119.591) | −0.668 | .511 | ||||
| Control | 5.365 (124.007) | 0.221 | .827 | 29.711 (170.228) | 0.890 | .382 | 24.346 (106.030) | 1.171 | .253 | ||||
Abbreviations: ANOVA, analysis of variance; T0, baseline; T1, 12-weeks postintervention; T2, 3-month follow-up; CRF, cancer-related fatigue; E1, Qigong exercise group; E2, stress management group; FOR, fear of recurrence; QOL, quality of life; SDNN, standard deviation of normal R-R intervals, the index of overall autonomic nervous system activity; TP, total power, the index of overall activity heart rate variability; HF, high frequency, the index of parasympathetic nerve activity.
Paired sample t test.
One-way ANOVA.
P < .01, ***P < .001 (2-tailed test).
Time Effects of 3 Groups From AR1 Model of GEE Analysis (N = 80).
| DV | IV | Estimate β | SE | Wald χ2 |
|
|---|---|---|---|---|---|
| CRF | Intercept | 2.402 | 0.138 | 303.075 | <.001 |
| E1 vs control group | 0.173 | 0.182 | 0.903 | .342 | |
| E2 vs control group | 0.259 | 0.161 | 2.575 | .109 | |
| T1-T0 | −0.140 | 0.060 | 5.344 | .021 | |
| T2-T0 | −0.139 | 0.635 | 4.777 | .029 | |
| FOR | Intercept | 2.422 | 0.143 | 286.048 | <.001 |
| E1 vs control group | −0.094 | 0.185 | 0.258 | .611 | |
| E2 vs control group | 0.119 | 0.196 | 0.364 | .546 | |
| T1-T0 | −0.098 | 0.063 | 2.393 | .122 | |
| T2-T0 | −0.108 | 0.068 | 2.439 | .118 | |
| QOL | Intercept | 3.953 | 0.125 | 997.134 | <.001 |
| E1 vs control group | −0.014 | 0.153 | 0.008 | .928 | |
| E2 vs control group | −0.062 | 0.156 | 0.158 | .691 | |
| T1-T0 | 0.084 | 0.052 | 2.595 | .107 | |
| T2-T0 | 0.038 | 0.056 | 0.448 | .503 | |
| SDNN | Intercept | 29.883 | 2.104 | 201.597 | <.001 |
| E1 vs control group | −4.446 | 2.765 | 2.585 | .108 | |
| E2 vs control group | −3.897 | 2.393 | 2.651 | .103 | |
| T1-T0 | 4.245 | 0.956 | 19.682 | <.001 | |
| T2-T0 | 1.213 | 1.188 | 1.043 | .307 | |
| TP | Intercept | 492.471 | 72.249 | 46.462 | <.001 |
| E1 vs control group | −105.858 | 91.606 | 1.335 | .248 | |
| E2 vs control group | −98.154 | 78.120 | 1.579 | .209 | |
| T1-T0 | 129.728 | 39.815 | 10.616 | .001 | |
| T2-T0 | 31.413 | 41.245 | 0.580 | .446 | |
| HF | Intercept | 104.976 | 20.797 | 25.479 | <.001 |
| E1 vs control group | −37.619 | 26.734 | 1.980 | .159 | |
| E2 vs control group | −19.075 | 27.803 | 0.471 | .493 | |
| T1-T0 | 25.326 | 10.018 | 6.391 | .011 | |
| T2-T0 | 16.421 | 14.800 | 1.231 | .267 |
Abbreviations: AR, autoregressive; GEE, generalized estimating equation; DV, dependent variable; IV, independent variable; SE, standard error; CRF, cancer-related fatigue; E1, Qigong exercise group; E2, stress management group; T0, baseline; T1, 12-week postintervention; T2, 3-month follow-up; FOR, fear of recurrence; QOL, quality of life; SDNN, standard deviation of normal R-R intervals, the index of overall autonomic nervous system activity; TP, total power, the index of overall activity heart rate variability; HF, high frequency, the index of parasympathetic nerve activity.
P < .05, **P < .01, ***P < .001 (2-tailed test).